Published in Nat Rev Immunol on May 01, 2009
Human nutrition, the gut microbiome and the immune system. Nature (2011) 7.77
The PD-1 pathway in tolerance and autoimmunity. Immunol Rev (2010) 5.99
PI3K and cancer: lessons, challenges and opportunities. Nat Rev Drug Discov (2014) 4.81
Effective and selective targeting of leukemia cells using a TORC1/2 kinase inhibitor. Nat Med (2010) 3.26
Regulation of immune responses by mTOR. Annu Rev Immunol (2011) 3.08
Regulation and function of mTOR signalling in T cell fate decisions. Nat Rev Immunol (2012) 2.79
An oscillatory switch in mTOR kinase activity sets regulatory T cell responsiveness. Immunity (2010) 2.71
Interleukin-2 at the crossroads of effector responses, tolerance, and immunotherapy. Immunity (2013) 2.69
The S1P(1)-mTOR axis directs the reciprocal differentiation of T(H)1 and T(reg) cells. Nat Immunol (2010) 2.11
How tolerogenic dendritic cells induce regulatory T cells. Adv Immunol (2010) 2.11
Mammalian target of rapamycin controls dendritic cell development downstream of Flt3 ligand signaling. Immunity (2010) 2.05
Rapamycin/IL-2 combination therapy in patients with type 1 diabetes augments Tregs yet transiently impairs β-cell function. Diabetes (2012) 2.02
Mammalian target of rapamycin (mTOR) inhibition as a potential antiepileptogenic therapy: From tuberous sclerosis to common acquired epilepsies. Epilepsia (2009) 1.98
Generation of effector CD8+ T cells and their conversion to memory T cells. Immunol Rev (2010) 1.85
PI3K signalling in B- and T-lymphocytes: new developments and therapeutic advances. Biochem J (2012) 1.56
mTOR and GSK-3 shape the CD4+ T-cell stimulatory and differentiation capacity of myeloid DCs after exposure to LPS. Blood (2010) 1.45
CD4(+)Foxp3(+) regulatory T cell therapy in transplantation. J Mol Cell Biol (2011) 1.45
Constitutive reductions in mTOR alter cell size, immune cell development, and antibody production. Blood (2010) 1.44
mTOR Inhibition Attenuates Dextran Sulfate Sodium-Induced Colitis by Suppressing T Cell Proliferation and Balancing TH1/TH17/Treg Profile. PLoS One (2016) 1.41
The role of mTOR in memory CD8 T-cell differentiation. Immunol Rev (2010) 1.41
Cutting edge: Rapamycin augments pathogen-specific but not graft-reactive CD8+ T cell responses. J Immunol (2010) 1.38
Role of mTOR signaling in tumor cell motility, invasion and metastasis. Curr Protein Pept Sci (2011) 1.37
Treg-therapy allows mixed chimerism and transplantation tolerance without cytoreductive conditioning. Am J Transplant (2010) 1.36
Mammalian target of rapamycin inhibition and alloantigen-specific regulatory T cells synergize to promote long-term graft survival in immunocompetent recipients. J Immunol (2009) 1.35
Regulation of T-cell survival and mitochondrial homeostasis by TSC1. Eur J Immunol (2011) 1.34
Pharmacologic induction of CD8+ T cell memory: better living through chemistry. Sci Transl Med (2009) 1.34
Chikungunya virus-induced autophagy delays caspase-dependent cell death. J Exp Med (2012) 1.34
Temsirolimus, an mTOR inhibitor, enhances anti-tumour effects of heat shock protein cancer vaccines. Br J Cancer (2011) 1.33
mTOR kinase inhibitor AZD8055 enhances the immunotherapeutic activity of an agonist CD40 antibody in cancer treatment. Cancer Res (2011) 1.28
Induction of T cell anergy: integration of environmental cues and infectious tolerance. Curr Opin Immunol (2010) 1.28
Regulation of innate immune cell function by mTOR. Nat Rev Immunol (2015) 1.27
Regulatory T cells as therapeutic targets in rheumatoid arthritis. Nat Rev Rheumatol (2009) 1.26
Platelets: versatile effector cells in hemostasis, inflammation, and the immune continuum. Semin Immunopathol (2011) 1.26
Mammalian target of rapamycin regulates neutrophil extracellular trap formation via induction of hypoxia-inducible factor 1 α. Blood (2012) 1.25
Sirolimus enhances the magnitude and quality of viral-specific CD8+ T-cell responses to vaccinia virus vaccination in rhesus macaques. Am J Transplant (2011) 1.23
Aptamer-targeted inhibition of mTOR in T cells enhances antitumor immunity. J Clin Invest (2014) 1.22
Regulatory dendritic cell infusion prolongs kidney allograft survival in nonhuman primates. Am J Transplant (2013) 1.22
Innate control of B cell responses. Trends Immunol (2011) 1.21
Transplantation tolerance through mixed chimerism. Nat Rev Nephrol (2010) 1.17
Rapamycin unbalances the polarization of human macrophages to M1. Immunology (2013) 1.17
mTOR, linking metabolism and immunity. Semin Immunol (2013) 1.17
Amino acid catabolism: a pivotal regulator of innate and adaptive immunity. Immunol Rev (2012) 1.16
Prostaglandin E2 activates and utilizes mTORC2 as a central signaling locus for the regulation of mast cell chemotaxis and mediator release. J Biol Chem (2010) 1.14
The role of tuberous sclerosis complex 1 in regulating innate immunity. J Immunol (2012) 1.13
TSC1/2 signaling complex is essential for peripheral naïve CD8+ T cell survival and homeostasis in mice. PLoS One (2012) 1.12
Therapeutic role of mammalian target of rapamycin (mTOR) inhibition in preventing epileptogenesis. Neurosci Lett (2011) 1.12
mTOR and lymphocyte metabolism. Curr Opin Immunol (2013) 1.11
B7-H1-dependent sex-related differences in tumor immunity and immunotherapy responses. J Immunol (2010) 1.10
Beyond chemotherapy: new agents for targeted treatment of lymphoma. Nat Rev Clin Oncol (2010) 1.10
Mammalian target of rapamycin in spinal cord neurons mediates hypersensitivity induced by peripheral inflammation. Neuroscience (2010) 1.10
Rapamycin ameliorates dystrophic phenotype in mdx mouse skeletal muscle. Mol Med (2011) 1.09
Mammalian target of rapamycin integrates diverse inputs to guide the outcome of antigen recognition in T cells. J Immunol (2012) 1.08
Combination of temsirolimus (CCI-779) with chemoradiation in newly diagnosed glioblastoma multiforme (GBM) (NCCTG trial N027D) is associated with increased infectious risks. Clin Cancer Res (2010) 1.08
Tuberous sclerosis 1 (Tsc1)-dependent metabolic checkpoint controls development of dendritic cells. Proc Natl Acad Sci U S A (2013) 1.08
Short-term treatment with rapamycin and dietary restriction have overlapping and distinctive effects in young mice. J Gerontol A Biol Sci Med Sci (2012) 1.07
Targeting TOR dependence in cancer. Oncotarget (2010) 1.07
Novel inhibitors of the calcineurin/NFATc hub - alternatives to CsA and FK506? Cell Commun Signal (2009) 1.06
Dendritic cells and regulation of graft-versus-host disease and graft-versus-leukemia activity. Blood (2012) 1.06
Tpl2 ablation promotes intestinal inflammation and tumorigenesis in Apcmin mice by inhibiting IL-10 secretion and regulatory T-cell generation. Proc Natl Acad Sci U S A (2012) 1.04
mTOR inhibition activates overall protein degradation by the ubiquitin proteasome system as well as by autophagy. Proc Natl Acad Sci U S A (2015) 1.03
Combining mTor inhibitors with rapamycin-resistant T cells: a two-pronged approach to tumor elimination. Mol Ther (2011) 1.03
Update on staphylococcal superantigen-induced signaling pathways and therapeutic interventions. Toxins (Basel) (2013) 1.03
Pathogenic mechanisms in systemic lupus erythematosus. Autoimmunity (2010) 1.02
The staphylococcal enterotoxin (SE) family: SEB and siblings. Virulence (2013) 1.02
Homeostasis and the importance for a balance between AKT/mTOR activity and intracellular signaling. Curr Med Chem (2012) 1.02
Critical role of the mTOR pathway in development and function of myeloid-derived suppressor cells in lal-/- mice. Am J Pathol (2013) 1.02
Immunology: A metabolic switch to memory. Nature (2009) 1.01
1-Benzyl-3-cetyl-2-methylimidazolium iodide (NH125) induces phosphorylation of eukaryotic elongation factor-2 (eEF2): a cautionary note on the anticancer mechanism of an eEF2 kinase inhibitor. J Biol Chem (2011) 1.00
Emerging new pathways of pathogenesis and targets for treatment in systemic lupus erythematosus and Sjogren's syndrome. Curr Opin Rheumatol (2009) 0.99
Synergy between rapamycin and FLT3 ligand enhances plasmacytoid dendritic cell-dependent induction of CD4+CD25+FoxP3+ Treg. Blood (2015) 0.99
Tolerogenic dendritic cells: all present and correct? Am J Transplant (2010) 0.97
Rapamycin inhibits anal carcinogenesis in two preclinical animal models. Cancer Prev Res (Phila) (2010) 0.96
Resveratrol inhibits inflammatory responses via the mammalian target of rapamycin signaling pathway in cultured LPS-stimulated microglial cells. PLoS One (2012) 0.96
Induced regulatory T cells: mechanisms of conversion and suppressive potential. Hum Immunol (2012) 0.95
Dynamic modulation of innate immune response by varying dosages of lipopolysaccharide (LPS) in human monocytic cells. J Biol Chem (2014) 0.94
Cot/tpl2-MKK1/2-Erk1/2 controls mTORC1-mediated mRNA translation in Toll-like receptor-activated macrophages. Mol Biol Cell (2012) 0.94
Controlled release formulations of IL-2, TGF-β1 and rapamycin for the induction of regulatory T cells. J Control Release (2012) 0.94
Pharmacological regulators of autophagy and their link with modulators of lupus disease. Br J Pharmacol (2014) 0.93
Critical role of the tumor suppressor tuberous sclerosis complex 1 in dendritic cell activation of CD4 T cells by promoting MHC class II expression via IRF4 and CIITA. J Immunol (2013) 0.93
Intermittent supplementation with rapamycin as a dietary restriction mimetic. Aging (Albany NY) (2011) 0.93
Rapamycin increases the yield and effector function of human γδ T cells stimulated in vitro. Cancer Immunol Immunother (2010) 0.92
Bioinspired controlled release of CCL22 recruits regulatory T cells in vivo. Adv Mater (2012) 0.91
Small-molecule protein kinase inhibitors and their effects on the immune system: implications for cancer treatment. Immunotherapy (2011) 0.91
TNFAIP3 promotes survival of CD4 T cells by restricting MTOR and promoting autophagy. Autophagy (2015) 0.91
Interleukin-21 promotes germinal center reaction by skewing the follicular regulatory T cell to follicular helper T cell balance in autoimmune BXD2 mice. Arthritis Rheumatol (2014) 0.91
The role of mTOR signaling pathway in spinal cord injury. Cell Cycle (2012) 0.90
Mammalian target of rapamycin (mTOR) regulates TLR3 induced cytokines in human oral keratinocytes. Mol Immunol (2010) 0.90
Paradoxical aspects of rapamycin immunobiology in transplantation. Am J Transplant (2011) 0.90
Rapamycin protects mice from staphylococcal enterotoxin B-induced toxic shock and blocks cytokine release in vitro and in vivo. Antimicrob Agents Chemother (2010) 0.90
Mammalian target of rapamycin regulates IL-10 and resistance to Pseudomonas aeruginosa corneal infection. J Immunol (2013) 0.90
Inhibition of protein kinase C delta attenuates allergic airway inflammation through suppression of PI3K/Akt/mTOR/HIF-1 alpha/VEGF pathway. PLoS One (2013) 0.90
Immunosuppressive and anti-inflammatory properties of engineered nanomaterials. Br J Pharmacol (2014) 0.90
Similarities in features of autism and asthma and a possible link to acetaminophen use. Med Hypotheses (2009) 0.89
Murine dendritic cell rapamycin-resistant and rictor-independent mTOR controls IL-10, B7-H1, and regulatory T-cell induction. Blood (2013) 0.89
Low dose rapamycin exacerbates autoimmune experimental uveitis. PLoS One (2012) 0.89
mTOR signaling inhibition modulates macrophage/microglia-mediated neuroinflammation and secondary injury via regulatory T cells after focal ischemia. J Immunol (2014) 0.89
Heterogeneity within T Cell Memory: Implications for Transplant Tolerance. Front Immunol (2012) 0.89
Combined treatment of rapamycin and dietary restriction has a larger effect on the transcriptome and metabolome of liver. Aging Cell (2013) 0.88
Immunotherapeutic modulation of the suppressive liver and tumor microenvironments. Int Immunopharmacol (2011) 0.88
Beneficial metabolic effects of rapamycin are associated with enhanced regulatory cells in diet-induced obese mice. PLoS One (2014) 0.88
TOR signaling in growth and metabolism. Cell (2006) 35.29
Regulatory T cells and immune tolerance. Cell (2008) 18.77
mTOR inhibition induces upstream receptor tyrosine kinase signaling and activates Akt. Cancer Res (2006) 18.44
Prolonged rapamycin treatment inhibits mTORC2 assembly and Akt/PKB. Mol Cell (2006) 18.36
Rictor, a novel binding partner of mTOR, defines a rapamycin-insensitive and raptor-independent pathway that regulates the cytoskeleton. Curr Biol (2004) 16.83
Interleukin-12 and the regulation of innate resistance and adaptive immunity. Nat Rev Immunol (2003) 15.65
IL-33, an interleukin-1-like cytokine that signals via the IL-1 receptor-related protein ST2 and induces T helper type 2-associated cytokines. Immunity (2005) 14.95
IRF-7 is the master regulator of type-I interferon-dependent immune responses. Nature (2005) 13.23
An ATP-competitive mammalian target of rapamycin inhibitor reveals rapamycin-resistant functions of mTORC1. J Biol Chem (2009) 12.73
Mammalian TOR complex 2 controls the actin cytoskeleton and is rapamycin insensitive. Nat Cell Biol (2004) 12.12
mTOR and cancer: insights into a complex relationship. Nat Rev Cancer (2006) 11.86
Growing roles for the mTOR pathway. Curr Opin Cell Biol (2005) 11.66
A mammalian protein targeted by G1-arresting rapamycin-receptor complex. Nature (1994) 11.50
Ablation in mice of the mTORC components raptor, rictor, or mLST8 reveals that mTORC2 is required for signaling to Akt-FOXO and PKCalpha, but not S6K1. Dev Cell (2006) 11.48
Tor, a phosphatidylinositol kinase homologue, controls autophagy in yeast. J Biol Chem (1998) 10.77
Targets for cell cycle arrest by the immunosuppressant rapamycin in yeast. Science (1991) 10.16
The TSC1-2 tumor suppressor controls insulin-PI3K signaling via regulation of IRS proteins. J Cell Biol (2004) 9.71
Tor-mediated induction of autophagy via an Apg1 protein kinase complex. J Cell Biol (2000) 9.61
RAFT1: a mammalian protein that binds to FKBP12 in a rapamycin-dependent fashion and is homologous to yeast TORs. Cell (1994) 8.71
Akt regulates growth by directly phosphorylating Tsc2. Nat Cell Biol (2002) 8.04
TSC2 integrates Wnt and energy signals via a coordinated phosphorylation by AMPK and GSK3 to regulate cell growth. Cell (2006) 7.49
Activation of Akt and eIF4E survival pathways by rapamycin-mediated mammalian target of rapamycin inhibition. Cancer Res (2005) 7.34
Deacetylase inhibition promotes the generation and function of regulatory T cells. Nat Med (2007) 6.61
Rapamycin selectively expands CD4+CD25+FoxP3+ regulatory T cells. Blood (2005) 6.49
Smad3 and NFAT cooperate to induce Foxp3 expression through its enhancer. Nat Immunol (2007) 6.22
Antigen-loading compartments for major histocompatibility complex class II molecules continuously receive input from autophagosomes. Immunity (2006) 6.17
The AKT-mTOR axis regulates de novo differentiation of CD4+Foxp3+ cells. J Exp Med (2008) 6.07
T cell receptor signaling controls Foxp3 expression via PI3K, Akt, and mTOR. Proc Natl Acad Sci U S A (2008) 5.97
Foxp3 in control of the regulatory T cell lineage. Nat Immunol (2007) 5.94
mTOR.RICTOR is the Ser473 kinase for Akt/protein kinase B in 3T3-L1 adipocytes. J Biol Chem (2005) 5.62
GbetaL, a positive regulator of the rapamycin-sensitive pathway required for the nutrient-sensitive interaction between raptor and mTOR. Mol Cell (2003) 5.21
mSin1 is necessary for Akt/PKB phosphorylation, and its isoforms define three distinct mTORC2s. Curr Biol (2006) 5.06
Phosphatidylinositol-3-OH kinase and nutrient-sensing mTOR pathways control T lymphocyte trafficking. Nat Immunol (2008) 4.69
Regulatory T-cell immunotherapy for tolerance to self antigens and alloantigens in humans. Nat Rev Immunol (2007) 4.55
The TSC-mTOR signaling pathway regulates the innate inflammatory response. Immunity (2008) 4.44
Rapamycin (AY-22,989), a new antifungal antibiotic. I. Taxonomy of the producing streptomycete and isolation of the active principle. J Antibiot (Tokyo) (1975) 4.37
A two-step process for thymic regulatory T cell development. Immunity (2008) 4.29
Rapamycin promotes expansion of functional CD4+CD25+FOXP3+ regulatory T cells of both healthy subjects and type 1 diabetic patients. J Immunol (2006) 4.23
Expanding mTOR signaling. Cell Res (2007) 4.01
Everolimus for the prevention of allograft rejection and vasculopathy in cardiac-transplant recipients. N Engl J Med (2003) 3.61
Linked T cell receptor and cytokine signaling govern the development of the regulatory T cell repertoire. Immunity (2008) 3.56
WNT signalling in the immune system: WNT is spreading its wings. Nat Rev Immunol (2008) 3.46
Toll-like receptor-mediated induction of type I interferon in plasmacytoid dendritic cells requires the rapamycin-sensitive PI(3)K-mTOR-p70S6K pathway. Nat Immunol (2008) 3.43
PI3K-mediated negative feedback regulation of IL-12 production in DCs. Nat Immunol (2002) 3.37
Inhibition of CD4+CD25+ regulatory T-cell function by calcineurin-dependent interleukin-2 production. Blood (2006) 3.33
RAPT1, a mammalian homolog of yeast Tor, interacts with the FKBP12/rapamycin complex. Proc Natl Acad Sci U S A (1994) 3.30
Differential impact of mammalian target of rapamycin inhibition on CD4+CD25+Foxp3+ regulatory T cells compared with conventional CD4+ T cells. Blood (2007) 3.27
Disruption of the mouse mTOR gene leads to early postimplantation lethality and prohibits embryonic stem cell development. Mol Cell Biol (2004) 3.20
ST2 is an inhibitor of interleukin 1 receptor and Toll-like receptor 4 signaling and maintains endotoxin tolerance. Nat Immunol (2004) 3.19
Autophagy enhances the efficacy of BCG vaccine by increasing peptide presentation in mouse dendritic cells. Nat Med (2009) 3.17
Blocking both signal 1 and signal 2 of T-cell activation prevents apoptosis of alloreactive T cells and induction of peripheral allograft tolerance. Nat Med (1999) 3.17
Rapamycin derivatives reduce mTORC2 signaling and inhibit AKT activation in AML. Blood (2006) 3.13
Selective survival of naturally occurring human CD4+CD25+Foxp3+ regulatory T cells cultured with rapamycin. J Immunol (2007) 3.09
The known unknowns of antigen processing and presentation. Nat Rev Immunol (2008) 2.85
Sirolimus: its discovery, biological properties, and mechanism of action. Transplant Proc (2003) 2.71
Rapamycin-conditioned dendritic cells are poor stimulators of allogeneic CD4+ T cells, but enrich for antigen-specific Foxp3+ T regulatory cells and promote organ transplant tolerance. J Immunol (2007) 2.61
Contrasting effects of cyclosporine and rapamycin in de novo generation of alloantigen-specific regulatory T cells. Am J Transplant (2007) 2.61
Mammalian target of rapamycin and glycogen synthase kinase 3 differentially regulate lipopolysaccharide-induced interleukin-12 production in dendritic cells. Blood (2008) 2.53
Improved survival in lymphoma patients receiving sirolimus for graft-versus-host disease prophylaxis after allogeneic hematopoietic stem-cell transplantation with reduced-intensity conditioning. J Clin Oncol (2008) 2.44
Reversal of in vitro T cell clonal anergy by IL-2 stimulation. Int Immunol (1992) 2.39
Rapamycin-treated, alloantigen-pulsed host dendritic cells induce ag-specific T cell regulation and prolong graft survival. Am J Transplant (2005) 2.32
Translational control of the innate immune response through IRF-7. Nature (2008) 2.30
IL-15 and IL-2: a matter of life and death for T cells in vivo. Nat Med (2001) 2.29
Rapamycin, and not cyclosporin A, preserves the highly suppressive CD27+ subset of human CD4+CD25+ regulatory T cells. Blood (2005) 2.17
Altered activation of AKT is required for the suppressive function of human CD4+CD25+ T regulatory cells. Blood (2006) 2.12
Rapamycin inhibits IL-4--induced dendritic cell maturation in vitro and dendritic cell mobilization and function in vivo. Blood (2003) 2.12
Prevention of T cell anergy by signaling through the gamma c chain of the IL-2 receptor. Science (1994) 2.10
LST8 negatively regulates amino acid biosynthesis as a component of the TOR pathway. J Cell Biol (2003) 2.01
The Pim kinases control rapamycin-resistant T cell survival and activation. J Exp Med (2005) 1.99
Rapamycin in transplantation: a review of the evidence. Kidney Int (2001) 1.97
PTEN inhibits IL-2 receptor-mediated expansion of CD4+ CD25+ Tregs. J Clin Invest (2006) 1.93
Transient aggregation of ubiquitinated proteins during dendritic cell maturation. Nature (2002) 1.92
Interleukin-2 receptor signaling in regulatory T cell development and homeostasis. Immunol Lett (2007) 1.91
Novel roles of Akt and mTOR in suppressing TGF-beta/ALK5-mediated Smad3 activation. EMBO J (2005) 1.85
Prolonged TCR/CD28 engagement drives IL-2-independent T cell clonal expansion through signaling mediated by the mammalian target of rapamycin. J Immunol (2006) 1.81
Rapamycin, not cyclosporine, permits thymic generation and peripheral preservation of CD4+ CD25+ FoxP3+ T cells. Bone Marrow Transplant (2007) 1.79
Modulation of insulin-stimulated degradation of human insulin receptor substrate-1 by Serine 312 phosphorylation. J Biol Chem (2003) 1.75
Regulatory T cells and T cell depletion: role of immunosuppressive drugs. J Am Soc Nephrol (2007) 1.75
Sirolimus, tacrolimus, and low-dose methotrexate for graft-versus-host disease prophylaxis in mismatched related donor or unrelated donor transplantation. Blood (2003) 1.73
Cutting edge: Foxp3-mediated induction of pim 2 allows human T regulatory cells to preferentially expand in rapamycin. J Immunol (2008) 1.71
Activation of the mammalian target of rapamycin pathway acutely inhibits insulin signaling to Akt and glucose transport in 3T3-L1 and human adipocytes. Endocrinology (2004) 1.71
Calcineurin inhibitors, but not rapamycin, reduce percentages of CD4+CD25+FOXP3+ regulatory T cells in renal transplant recipients. Transplantation (2006) 1.68
Rapamycin and interleukin-10 treatment induces T regulatory type 1 cells that mediate antigen-specific transplantation tolerance. Diabetes (2006) 1.65
Differential effects of immunosuppressive drugs on chemokine receptor CCR7 in human monocyte-derived dendritic cells: selective upregulation by rapamycin. Transplantation (2006) 1.58
STAT5-signaling cytokines regulate the expression of FOXP3 in CD4+CD25+ regulatory T cells and CD4+CD25- effector T cells. Int Immunol (2008) 1.58
Rapamycin enriches for CD4(+) CD25(+) CD27(+) Foxp3(+) regulatory T cells in ex vivo-expanded CD25-enriched products from healthy donors and patients with multiple sclerosis. Cytotherapy (2007) 1.58
Rapamycin inhibits macropinocytosis and mannose receptor-mediated endocytosis by bone marrow-derived dendritic cells. Blood (2002) 1.53
The emerging role of T cell Ig mucin 1 in alloimmune responses in an experimental mouse transplant model. J Clin Invest (2008) 1.50
Making regulatory T cells with defined antigen specificity: role in autoimmunity and cancer. Immunol Rev (2006) 1.50
Rapamycin monotherapy in patients with type 1 diabetes modifies CD4+CD25+FOXP3+ regulatory T-cells. Diabetes (2008) 1.49
The solution structure of the FATC domain of the protein kinase target of rapamycin suggests a role for redox-dependent structural and cellular stability. J Biol Chem (2005) 1.49
The kinases aurora B and mTOR regulate the G1-S cell cycle progression of T lymphocytes. Nat Immunol (2006) 1.49
The influence of immunosuppressive drugs on tolerance induction through bone marrow transplantation with costimulation blockade. Blood (2002) 1.49
Induction of tolerance in type 1 diabetes via both CD4+CD25+ T regulatory cells and T regulatory type 1 cells. Diabetes (2006) 1.48
Mammalian target of rapamycin (mTOR) orchestrates the defense program of innate immune cells. Eur J Immunol (2008) 1.46
Drug eluting stents: an updated meta-analysis of randomised controlled trials. Heart (2005) 1.45
Rapamycin protects allografts from rejection while simultaneously attacking tumors in immunosuppressed mice. Transplantation (2004) 1.40
Use of sirolimus in solid organ transplantation. Drugs (2007) 1.40
Rapamycin-conditioned dendritic cells are poor stimulators of allogeneic CD4+ T cells, but enrich for antigen-specific Foxp3+ T regulatory cells and promote organ transplant tolerance. J Immunol (2007) 2.61
High PD-L1/CD86 ratio on plasmacytoid dendritic cells correlates with elevated T-regulatory cells in liver transplant tolerance. Transplantation (2008) 1.85
"Alternatively activated" dendritic cells preferentially secrete IL-10, expand Foxp3+CD4+ T cells, and induce long-term organ allograft survival in combination with CTLA4-Ig. J Immunol (2006) 1.30
Low TLR4 expression by liver dendritic cells correlates with reduced capacity to activate allogeneic T cells in response to endotoxin. J Immunol (2005) 1.14
Human induced pluripotent stem cell-derived models to investigate human cytomegalovirus infection in neural cells. PLoS One (2012) 1.11
Poor allostimulatory function of liver plasmacytoid DC is associated with pro-apoptotic activity, dependent on regulatory T cells. J Hepatol (2008) 1.10
Dendritic cells and regulation of graft-versus-host disease and graft-versus-leukemia activity. Blood (2012) 1.06
IL-27 production and STAT3-dependent upregulation of B7-H1 mediate immune regulatory functions of liver plasmacytoid dendritic cells. J Immunol (2012) 1.06
Rapamycin-conditioned, alloantigen-pulsed dendritic cells promote indefinite survival of vascularized skin allografts in association with T regulatory cell expansion. Transpl Immunol (2007) 1.05
Endotoxin modulates the capacity of CpG-activated liver myeloid DC to direct Th1-type responses. Eur J Immunol (2006) 0.97
Selective expansion of allogeneic regulatory T cells by hepatic stellate cells: role of endotoxin and implications for allograft tolerance. J Immunol (2012) 0.96
Induced regulatory T cells: mechanisms of conversion and suppressive potential. Hum Immunol (2012) 0.95
Controlled release formulations of IL-2, TGF-β1 and rapamycin for the induction of regulatory T cells. J Control Release (2012) 0.94
Tolerogenic dendritic cell-regulatory T-cell interaction and the promotion of transplant tolerance. Transplantation (2009) 0.92
Bioinspired controlled release of CCL22 recruits regulatory T cells in vivo. Adv Mater (2012) 0.91
Implications for Interleukin-33 in solid organ transplantation. Cytokine (2013) 0.89
Murine dendritic cell rapamycin-resistant and rictor-independent mTOR controls IL-10, B7-H1, and regulatory T-cell induction. Blood (2013) 0.89
Migratory, and not lymphoid-resident, dendritic cells maintain peripheral self-tolerance and prevent autoimmunity via induction of iTreg cells. Blood (2012) 0.86
Rhesus monkey immature monocyte-derived dendritic cells generate alloantigen-specific regulatory T cells from circulating CD4+CD127-/lo T cells. Transplantation (2009) 0.85
Frontiers of immunological tolerance. Methods Mol Biol (2007) 0.84
The immune response is initiated by dendritic cells via interaction with microorganisms and interleukin-2 production. J Infect Dis (2003) 0.83
Low TCR signal strength induces combined expansion of Th2 and regulatory T cell populations that protect mice from the development of type 1 diabetes. Diabetologia (2014) 0.82
Rapamycin-conditioned, alloantigen-pulsed myeloid dendritic cells present donor MHC class I/peptide via the semi-direct pathway and inhibit survival of antigen-specific CD8(+) T cells in vitro and in vivo. Transpl Immunol (2011) 0.82
Non-human primate regulatory T cells: current biology and implications for transplantation. Transplantation (2010) 0.81
Expression of invariant chain can cause an allele-dependent increase in the surface expression of MHC class I molecules. Immunogenetics (2002) 0.81
All-trans retinoic acid and rapamycin synergize with transforming growth factor-β1 to induce regulatory T cells but confer different migratory capacities. J Leukoc Biol (2013) 0.79
Cutting edge: Flt3 ligand mediates STAT3-independent expansion but STAT3-dependent activation of myeloid-derived suppressor cells. J Immunol (2014) 0.77
Taming inflammation by targeting cytokine signaling: new perspectives in the induction of transplantation tolerance. Immunotherapy (2014) 0.76
Flt3 ligand delivered in a pluronic formulation prolongs the survival of mice with orthotopic pancreatic adenocarcinoma. Cancer Biother Radiopharm (2007) 0.76
Abstract 11: the role of donor antigen persistance in maintaining immune tolerance to a vascularized composite allograft. Plast Reconstr Surg (2014) 0.75
Abstract 102: inflammatory mediators modulate alloreactive T cell susceptibility to immune-regulation in reconstructive transplantation. Plast Reconstr Surg (2014) 0.75